Where to be

5 can't-miss Houston events for entrepreneurs to close out 2018

Check out these conferences, shopping events, networking, and more. Getty Images

Before most of Houston completely checks out for the holidays, the city is playing host to a few major innovation-focused events. Learn from thought leaders, network, and even shop at these five events taking place this week and next.

Applied AI Summit Houston

Technology events organizer Re-Work is bringing a conference focused on all things artificial intelligence — and how it can affect your business. The conference takes place Thursday, November 29, to Friday, November 30, at the JW Marriott Houston Downtown and expects 60 speakers and over 450 attendees.

The event is co-located with Re-Work's other two-day conference focused on machine learning.

Learn more here.

Machine Learning for DevOps Summit Houston

Next door from the AI summit at the JW Marriott Houston Downtown will be another future-forward summit focused on machine learning for development operations. The two events share locations, and both have full-day schedules from Thursday, November 29, to Friday, November 30.

Learn how automation is going to affect the industry or your company and mingle with leaders of the industry.

Learn more here.

HX Capital Summit

Houston Exponential is hosting a full-day summit on Tuesday, December 4, at the Texas Medical Center's Innovation Institute in an attempt to bring more funding for startups in Houston.

"The HX Capital Summit is a forum to convene investors, entrepreneurs and other ecosystem stakeholders on a critical topic — attracting capital to fund high growth, high impact companies in Houston," says Gina Luna, board chair of Houston Exponential, on the event website. "This event is an opportunity to celebrate positive momentum and to continue to work on addressing our gaps in funding startups, so that Houston can benefit from the tremendous economic impact of their growth and eventual exits."

Learn more here.

The Greater Houston Partnership's Annual Houston Region Economic Outlook

On Wednesday, December 5, the Greater Houston Partnership is hosting a slew of industry experts at the Royal Sonesta Houston to discuss what to expect in 2019. The GHP's senior vice president of research, Patrick Jankowski, will be delivering the 2019 employment forecast for the Houston area for 2019.

The event consists of a panel, luncheon, and business expo. Registration and networking begins at 9:30 am, and the event concludes with a business expo from 1:30 to 2 pm.

Learn more here.

NextSeed's Night Market

In honor of the holidays, NextSeed is hosting its annual Night Market on Thursday, December 6, at 3 Greenway Plaza on the sixth floor. The event begins at 6:30 pm with a cocktail hour, followed by food, drinks, shopping, and mingling.

NextSeed is all about connecting startups and small businesses to their communities, so, in the same vein, the Night Market will be populated by small businesses — some are even NextSeed clients. Read more about NextSeed here.

Learn more here.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted